Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY
Total product sales of €64.0 millionIn-line with expectations; full-year guidance of €135 -150 million reaffirmedSolid cash position of €121.5 million as of end June 2026Reflects disciplined cash management and proceeds
Valneva's medicine sales dropped by about 30% compared to last year, and the company lost more money than it did before. But the company still has plenty of cash saved up and says it's on track for the year ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.